Caroline Seymour


N-803 BLA Undergoes Review For BCG-Unresponsive Non–Muscle Invasive Bladder Cancer in Situ

August 10, 2022

A biologics license application for the IL-15 superagonist N-803 has been accepted and the agent will be reviewed for the treatment of patients with Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer carcinoma in situ.

Mosunetuzumab Receives Priority Review Designation for Relapsed/Refractory Follicular Lymphoma

July 22, 2022

Mosunetuzumab, a CD20 and CD3 T-cell engaging bispecific antibody, received a priority review designation from the FDA for the treatment of patients with relapsed/refractory follicular lymphoma following at least 2 prior systemic therapies.

Superior Pathologic Complete Responses in NSCLC Tied to Durvalumab/Chemotherapy Combo

July 16, 2022

Phase 3 findings from the AEGEAN trial demonstrated that adding durvalumab to platinum-based chemotherapy regimens improved pathologic complete response and major pathologic response among patients with resectable non–small cell lung cancer.

RVd Plus ACST and Lenalidomide Maintenance Promote Efficacy in Newly Diagnosed Multiple Myeloma

June 08, 2022

Patients with multiple myeloma who received initial combination therapy with lenalidomide, bortezomib, and dexamethasone, plus autologous stem cell transplant, followed by lenalidomide maintenance, experienced improved progression-free survival.